摘要
目的:健脾化痰祛湿方是常见的中医处方,辅助化疗可提高非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的化疗效果,降低不良反应。本研究旨在分析健脾化痰祛湿方对放化疗脾虚痰湿证NSCLC患者免疫功能、疗效及预后的影响。方法:收集2020年12月至2023年1月在平顶山市第二人民医院治疗的72例NSCLC患者,分为对照组(n=36)和观察组(n=36)。对照组接受同步放化疗,观察组在同步放化疗的同时给予健脾化痰祛湿方口服治疗。比较2组患者短期疗效、免疫功能指标(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、肿瘤标志物、中医证候评分、SF-36生活质量问卷评分以及不良反应发生情况,随访并比较2组患者的无进展生存期(progression-free survival,PFS)和总生存期(overal survival,OS)。结果:2组患者治疗后的总有效率及疾病控制率差异均无统计学意义(均P>0.05)。治疗后观察组癌胚抗原(carcinoma embryonic antigen,CEA)、糖类抗原125(carbohydrate antigen 125,CA125)、神经元特异性烯醇化酶(neuron-specific enolase,NSE)水平,脱发、胃肠道反应、骨髓抑制、腹泻发生率均明显低于对照组,但CD3^(+)水平、CD4^(+)水平、CD4^(+)/CD8^(+)、中医证候评分及SF-36生活质量问卷评分均明显高于对照组(均P<0.05)。生存分析显示观察组PFS显著长于对照组(χ^(2)=5.313,P=0.021),但2组OS差异无统计学意义(χ^(2)=1.983,P=0.159)。结论:健脾化痰祛湿方同步放化疗可在一定程度上改善NSCLC患者的免疫功能及预后,降低血清肿瘤标志物水平,具有临床推广价值。
Objective:The Jianpi Huatan Qushi formula is a commonly used traditional Chinese medicine prescription.When used as an adjunct to chemotherapy,it may enhance the therapeutic efficacy in non-small cell lung cancer(NSCLC)and reduce adverse reactions.This study aims to evaluate the effect of the Jianpi Huatan Qushi formula on immune function,treatment efficacy,and prognosis in NSCLC patients with a traditional Chinese medicine diagnosis of spleen deficiency with phlegm-dampness undergoing concurrent chemoradiotherapy.Methods:A total of 72 NSCLC patients treated at Pingdingshan Second People’s Hospital between December 2020 and January 2023 were enrolled and divided into a control group(n=36)receiving standard concurrent chemoradiotherapy,and an observation group(n=36)receiving the same treatment plus oral Jianpi Huatan Qushi formula.The 2 groups were compared in terms of short-term efficacy,immune markers(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)),tumor markers,traditional Chinese medicine syndrome scores,SF-36 quality of life scores,and adverse reactions,and survival outcomes[progression-free survival(PFS)and overall survival(OS)].Results:There were no significantly significant differences in overall response rate or disease control rate between the 2 groups(P>0.05).Post-treatment levels of carcinoma embryonic antigen(CEA),carbohydrate antigen 125(CA125),and neuron-specific enolase(NSE),as well as the incidence of alopecia,gastrointestinal reactions,myelosuppression,and diarrhea were significantly lower in the observation group.In contrast,the observation group had significantly higher levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+)ratio,better traditional Chinese medicine syndrome scores,and higher SF-36 quality of life scores(all P<0.05).Survival analysis showed that PFS was significantly longer in the observation group(χ^(2)=5.313,P=0.021),while OS did not differ significantly(χ^(2)=1.983,P=0.159).Conclusion:The Jianpi Huatan Qushi formula,when combined with concurrent chemoradiotherapy,may improve immune function and prognosis in NSCLC patients,reduce serum tumor marker levels,and is associated with fewer adverse reactions.These findings suggest it has potential for broader clinical application.
作者
张公正
闫奇
ZHANG Gongzheng;YAN Qi(Department of Radiotherapy,Pingdingshan Second People’s Hospital,Pingdingshan 467000;Department of General Medicine,Pingdingshan Second People’s Hospital,Pingdingshan 467000,China)
出处
《临床与病理杂志》
2025年第3期275-282,共8页
Journal of Clinical and Pathological Research
关键词
健脾化痰祛湿方
非小细胞肺癌
同步放化疗
疗效
免疫功能
Jianpi Huatan Qushi formula
non-small cell lung cancer
concurrent chemoradiotherapy
therapeutic efficacy
immune function
